Gottlieb Uses ASCO Platform To Unveil Two Pilot Programs To Speed Drug Review
US FDA commissioner outlines plans to allow partial submissions as soon as database locks and to create joint sponsor-agency review documents.
You may also be interested in...
Applications no longer need to have ‘straightforward study designs’ to qualify for RTOR, but no aspect of the submission should be likely to require a longer review time, US FDA says in a final guidance on the expedited pathway.
Technology modernization efforts, the expansion of cloud-based submission capabilities, and the ongoing COVID-19 pandemic could serve as catalysts to broaden FDA’s Real-Time Oncology Review program beyond cancer therapeutics, Pfizer exec Richard Jahn says.
Genentech/AbbVie drug becomes the seventh product known to be pilot-testing US FDA's new pathway; our infographic details the program's goals and how it has been used so far for more efficient reviews of supplemental oncology indications.